世界病毒学杂志(英文版)最新文献

{"title":"COVID-19 in patients with pre-existing chronic liver disease - predictors of outcomes.","authors":"Dinesh Walia, Anoop Saraya, Deepak Gunjan","doi":"10.5501/wjv.v12.i1.30","DOIUrl":"10.5501/wjv.v12.i1.30","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) has affected patients with pre-existing chronic liver disease (CLD) in various ways. The maximum impact was seen on patients with underlying cirrhosis who have shown to have poor clinical outcomes in the form of increased risk of hepatic decompensation, acute-on-chronic liver failure, and even mortality. It is of paramount importance to identify various factors which are associated with unfavorable outcomes for prognostication and making informed management strategy. Many factors have been evaluated in different studies in patients with underlying CLD. Some of these factors include the severity of underlying chronic liver disease, comorbid conditions, age, and severity of COVID-19. Overall, the outcomes are not fav-orable in patients with cirrhosis as evidenced by data from various studies. The main purpose of this review is to identify the predictors of adverse clinical outcomes including mortality in patients with CLD for risk stratification, prognostication, and appropriate clinical management.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"12 1","pages":"30-43"},"PeriodicalIF":0.0,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/38/WJV-12-30.PMC9896592.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10667720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dipeptidyl peptidase 4 inhibitors in COVID-19: Beyond glycemic control.","authors":"Niya Narayanan,&nbsp;Dukhabandhu Naik,&nbsp;Jayaprakash Sahoo,&nbsp;Sadishkumar Kamalanathan","doi":"10.5501/wjv.v11.i6.399","DOIUrl":"https://doi.org/10.5501/wjv.v11.i6.399","url":null,"abstract":"<p><p>Coronavirus disease 2019 (COVID-19) is associated with a high risk of mortality and complications in patients with diabetes mellitus. Achieving good glycemic control is very important in diabetic patients to reduce complications and mortality due to COVID-19. Recent studies have shown the mortality benefit and anti-inflammatory effects of Dipeptidyl-peptidase-4 inhibitors (DPP-4i) in diabetic patients with COVID-19. DPP-4i may have a beneficial role in halting the severity of infection primarily by three routes, namely viral entry inhibition, anti-inflammatory and anti-fibrotic effects and glycemic control. This has raised the pro-mising hypothesis that DPP-4i might be an optimal strategy for treating COVID-19 in patients with diabetes. This review aims to summarise the possible therapeutic non-glycemic effects of DPP-4i in diabetic patients diagnosed with COVID-19 in the light of available evidence.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"399-410"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/4e/WJV-11-399.PMC9724202.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10364171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Monkeypox: An emerging zoonotic pathogen.","authors":"Masoumeh Beig, Mehrdad Mohammadi, Fatemeh Nafe Monfared, Somaieh Nasereslami","doi":"10.5501/wjv.v11.i6.426","DOIUrl":"10.5501/wjv.v11.i6.426","url":null,"abstract":"<p><p>Monkeypox virus (MPXV), which belongs to the orthopoxvirus genus, causes zoonotic viral disease. This review discusses the biology, epidemiology, and evolution of MPXV infection, particularly cellular, human, and viral factors, virus transmission dynamics, infection, and persistence in nature. This review also describes the role of recombination, gene loss, and gene gain in MPXV evol-vement and the role of signal transduction in MPXV infection and provides an overview of the current access to therapeutic options for the treatment and prevention of MPXV. Finally, this review highlighted gaps in knowledge and proposed future research endeavors to address the unresolved questions.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"426-434"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/03/a8/WJV-11-426.PMC9724206.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics of COVID-19 patients who underwent tracheostomy and its effect on outcome: A retrospective observational study.","authors":"Yudhyavir Singh,&nbsp;Kapil Dev Soni,&nbsp;Abhishek Singh,&nbsp;Nikita Choudhary,&nbsp;Fahina Perveen,&nbsp;Richa Aggarwal,&nbsp;Nishant Patel,&nbsp;Shailendra Kumar,&nbsp;Anjan Trikha","doi":"10.5501/wjv.v11.i6.477","DOIUrl":"https://doi.org/10.5501/wjv.v11.i6.477","url":null,"abstract":"<p><strong>Background: </strong>The exponential rise in Coronavirus disease 2019 (COVID-19) cases has resulted in an increased number of patients requiring prolonged ventilatory support and subsequent tracheostomy. With the limited availability of literature regarding the outcomes of COVID-19 patients with tracheostomy, we attempted to study the clinical characteristics and multiple parameters affecting the outcomes in these patients.</p><p><strong>Aim: </strong>To determine all-cause mortality following tracheostomy and its association with various risk factors in COVID-19 patients.</p><p><strong>Methods: </strong>This retrospective study included 73 adult COVID-19 patients admitted to the ICU between 1 April, 2020 and 30 September, 2021 who underwent tracheostomy as a result of acute respiratory failure due to COVID-19. The data collected included demographics (age, sex), comorbidities, type of oxygen support at admission, severity of COVID-19, complications, and other parameters such as admission to tracheostomy, intubation to tracheostomy, ICU stay, hospital stay, and outcome.</p><p><strong>Results: </strong>This study included 73 adult patients with an average age of 52 ± 16.67 years, of which 52% were men. The average time for admission to tracheostomy was 18.12 ± 12.98 days while intubation to tracheostomy was 11.97 ± 9 days. The mortality rate was 71.2% and 28.8% of patients were discharged alive. The mean duration of ICU and hospital stay was 25 ± 11 days and 28.21 ± 11.60 days, respectively. Greater age, severe COVID-19, mechanical ventilation, shock and acute kidney injury were associated with poor prognosis; however, early tracheostomy in intubated patients resulted in better outcomes.</p><p><strong>Conclusion: </strong>Patients with severe COVID-19 requiring mechanical ventilation have a poor prognosis but patients with early tracheostomy may benefit with no added risk. We recommend that the timing of tracheostomy be decided on a case-by-case basis and a well-designed randomised controlled trial should be performed to elucidate the potential benefit of early tracheostomy in such patients.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"477-484"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/83/WJV-11-477.PMC9724205.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10378500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cholestatic liver injury: A rare but fatal complication during and after COVID-19 infection.","authors":"Wachira Wongtanasarasin","doi":"10.5501/wjv.v11.i6.435","DOIUrl":"https://doi.org/10.5501/wjv.v11.i6.435","url":null,"abstract":"<p><p>The 2019 coronavirus disease (COVID-19), resulting from the severe acute respiratory syndrome 2 virus, has transformed our globe and provided a new perspective on respiratory tract infections. However, COVID-19 would not be recognized as a condition restricted to only pneumonia. This narrative review was conducted by searching manuscripts in several databases, including PubMed/ MEDLINE, Web of Science, and Reference Citation Analysis, from December 2019 to July 2022. Many studies have revealed a broad spectrum of potential systemic symptoms, including biliary complications. Although biliary injury has been observed in a very low proportion of COVID-19 patients, it is associated with increased mortalities and long-term morbidities. We identify a cholangiopathy condition in individuals during infection and after recovering from severe COVID-19, defined by a significant increase in serum alkaline phosphatase and signs of bile duct injury. Understanding the pathogeneses behind this condition would help us develop new techniques to prevent these complications. This review thoroughly discusses and summarizes the current information regarding COVID-19-associated cholangiopathy. In addition, the possible explanations for COVID-19-associated cholangiopathy are presented. Since the exact pathogenesis may not be concluded, this review could provide relevant information to encourage additional investigations shortly.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"435-442"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/17/70/WJV-11-435.PMC9724201.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9462233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of the pandemic on rehabilitation healthcare services in India: Breaking barriers.","authors":"Raktim Swarnakar,&nbsp;Shiv Lal Yadav","doi":"10.5501/wjv.v11.i6.502","DOIUrl":"https://doi.org/10.5501/wjv.v11.i6.502","url":null,"abstract":"<p><p>We would like to highlight the rehabilitation medicine perspective from India. Difficulties are impacted by the pandemic during this time, especially for people with disabilities. Awareness building among the public regarding the need for rehabilitation along with improvement in infrastructure is the key unmet need.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"502-504"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/8f/7e/WJV-11-502.PMC9724197.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Potential risk of liver injury in epileptic patients during COVID-19 pandemic.","authors":"Nasim Tabrizi, Athena Sharifi-Razavi","doi":"10.5501/wjv.v11.i6.467","DOIUrl":"10.5501/wjv.v11.i6.467","url":null,"abstract":"<p><p>Most of the antiseizure medications (ASMs) are metabolized in liver and many of them particularly first-generation ASMs have the potential to increase liver enzymes or induce liver injury. Hence, treatment of new onset seizures or epilepsy by ASMs during the course of coronavirus disease 2019 (COVID-19), which could potentially be complicated by hepatic dysfunction, is a challenging clinical issue. Intravenous form of levetiracetam which has no significant hepatic metabolism or drug-drug interaction is often a favorable option to control seizures in acute phase of COVID-19. Administration of enzyme inducer ASMs and valproate with the well-known hepatotoxicity and common drug interactions is not generally recommended. In patients with epilepsy who are under control with potentially hepatotoxic ASMs, close observation and cautious dose reduction or drug switch should be considered if any evidence of hepatic impairment exists. However, risks of possible breakthrough seizures should be weighed against benefits of lowering the hazard of liver injury. In patients with epilepsy who receive polytherapy with ASMs, transient dose modification with the tendency to increase the dose of ASMs with more favorable safety profile and less drug interaction and decrease the dose of drugs with main hepatic metabolism, high protein binding, potential to cause liver injury and known drug-drug reaction should be considered. Finally, decision making should be individualized based on patients' conditions and course of illness.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"467-476"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/c0/WJV-11-467.PMC9724200.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intensive care unit adaptations in the COVID-19 pandemic: Lessons learned.","authors":"Anwar Khedr, David Rokser, Jeanine Borge, Hannah Rushing, Greta Zoesch, Wade Johnson, Han-Yin Wang, April Lanz, Brian N Bartlett, Jessica Poehler, Salim Surani, Syed A Khan","doi":"10.5501/wjv.v11.i6.394","DOIUrl":"10.5501/wjv.v11.i6.394","url":null,"abstract":"<p><p>The coronavirus disease 2019 pandemic had deleterious effects on the healthcare systems around the world. To increase intensive care units (ICUs) bed capacities, multiple adaptations had to be made to increase surge capacity. In this editorial, we demonstrate the changes made by an ICU of a midwest community hospital in the United States. These changes included moving patients that used to be managed in the ICU to progressive care units, such as patients requiring non-invasive ventilation and high flow nasal cannula, ST-elevation myocardial infarction patients, and post-neurosurgery patients. Additionally, newer tactics were applied to the processes of assessing oxygen supply and demand, patient care rounds, and post-ICU monitoring.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"394-398"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4c/1c/WJV-11-394.PMC9724203.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10371650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of COVID-19 on children with autism.","authors":"Mohammed Al-Beltagi,&nbsp;Nermin Kamal Saeed,&nbsp;Adel Salah Bediwy,&nbsp;Rawan Alhawamdeh,&nbsp;Samara Qaraghuli","doi":"10.5501/wjv.v11.i6.411","DOIUrl":"https://doi.org/10.5501/wjv.v11.i6.411","url":null,"abstract":"<p><p>The coronavirus disease 2019 (COVID-19) pandemic affects all countries and populations worldwide, significantly impacting people with autism with a high risk of morbidity and mortality due to COVID-19. Approximately 25% of children with autism have an asymptomatic or symptomatic immune deficiency or dysfunction. In addition, they frequently have various comorbid conditions that increase the severity of COVID-19. In addition, severe COVID-19 during pregnancy may increase the risk of autism in the offspring. Furthermore, severe acute respiratory syndrome coronavirus 2 could target human nervous system tissues due to its neurotrophic effects. The COVID-19 pandemic intensely impacts many patients and families in the autism community, especially the complex management of autism-associated disorders during the complete lockdown. During the complete lockdown, children with autism had difficulties coping with the change in their routine, lack of access to special education services, limited physical space available, and problems related to food and sleep. Additionally, children with autism or intellectual disabilities are more liable to be abused by others during the pandemic when the standard community supports are no longer functioning to protect them. Early detection and vaccination of children with autism against COVID-19 are highly indicated. They should be prioritized for testing, vaccination, and proper management of COVID-19 and other infectious diseases. In this review, we discuss the various effects of COVID-19 on children with autism, the difficulties they face, the increased risk of infection during pregnancy, how to alleviate the impact of COVID-19, and how to correct the inequalities in children with autism.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"411-425"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cd/eb/WJV-11-411.PMC9724198.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10378502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global challenge with the SARS-CoV-2 omicron BA.2 (B.1.1.529.2) subvariant: Should we be concerned?","authors":"Jalil Roohani, Masoud Keikha","doi":"10.5501/wjv.v11.i6.496","DOIUrl":"10.5501/wjv.v11.i6.496","url":null,"abstract":"<p><p>BA.2 is a novel omicron offshoot of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has gone viral. There is limited knowledge regarding this variant of concern. Current evidence suggests that this variant is more contagious but less severe than previous SARS-CoV-2 variants. However, there is concern regarding the virus mutations that could influence pathogenicity, transmissibility, and immune evasion.</p>","PeriodicalId":61903,"journal":{"name":"世界病毒学杂志(英文版)","volume":"11 6","pages":"496-501"},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fb/3a/WJV-11-496.PMC9724199.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10378501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}